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Abstract
Immunohistochemical staining can be of great utility in differentiating various cutaneous
spindle cell neoplasms, particularly when the histomorphological appearance of the lesions is
inconclusive. Nuclear staining for ETS-related gene (ERG), a highly sensitive endothelial cell
marker, has seldom been studied in the context of cutaneous spindle cell neoplasms. Little is
known about its specificity for vascular differentiation. In this pilot study, immunohistochemical
analysis for ERG was performed on fifteen dermatofibromas (DF), ten keloids, and nine
dermatofibrosarcoma protuberans tumors (DFSP). Consistent nuclear expression of ERG was
found in DF [100% (15/15) of the lesions demonstrated >50% labeling of tumor cells with
moderate to strong intensity]. However, ERG expression was largely absent in DFSP [89% (8/9)
of the lesions demonstrating <50% labeling staining, generally of mild intensity] and
hypertrophic scars-keloids [80% (8/10) without expression]. Based on the results of this pilot
study, immunohistochemical staining for ERG may prove useful in helping to differentiate DF
from DFSP and hypertrophic scars in the context of partial biopsy sampling. If replicated in a
larger number of samples, this finding could mitigate the use of costly sequencing panels and
potentially avoid unnecessary re-excisions in certain contexts.
Introduction
Dermal-based spindled cell neoplasms comprise a heterogeneous group of tumors arising
from divergent cell lineages. These are characterized by the presence of elongated cells in
various configurations on light microscopy. [1] Similar to their soft tissue counterparts, these
neoplasms may demonstrate either benign, intermediate-grade, or malignant phenotypes. [2]
Dermatofibroma (DF), also known as fibrous histiocytoma, is the most commonly encountered

benign cutaneous mesenchymal tumor. Malignant spindled cell sarcomas in the skin are much
more infrequent (less than 1% of malignant tumors in the skin), with the most common being
dermatofibrosarcoma protuberans (DFSP), pleomorphic dermal sarcoma, and
leiomyosarcoma.[1] A pattern-based diagnostic approach is often taken when differentiating
these neoplasms, which includes consideration of tumor location, architectural features such as
size, depth, stroma, cellular configuration and cytomorphology.[1, 3] These parameters alone are
usually sufficient for the distinction between various entities, though immunohistochemical
staining is not infrequently required for additional diagnostic support.[4]
ERG is the nuclear protein product of the ETS-related gene (ERG), which serves as a
transcriptional regulator and affects angiogenesis and endothelial cell migration.[5, 6] ERG as an
immunohistochemical stain has several uses in clinical practice, most notably serving as a highly
sensitive endothelial cell marker.[7] It also exhibits positive staining in several chondrogenic
tumors, prostate adenocarcinomas, and other tumors with ERG gene rearrangements (e.g., ERGrearranged Ewing sarcoma).[8-12] The current use of ERG in dermatopathology has primarily
been limited to supporting vascular differentiation. However, strong and diffuse nuclear
expression of ERG has recently been reported in the setting of EWSR1-SMAD3 rearranged
fibroblastic tumor (ESFT), a newly described superficial-acral spindle cell neoplasm.[13, 14]
Similarly, diffuse staining for ERG has been reported in a few case studies of pseudomyogenic
hemangioendothelioma and epithelioid sarcoma.[15-17] With these few exceptions, data
regarding its overall specificity for vascular differentiation in the setting of commonly
encountered cutaneous spindle cell neoplasms is lacking.

Our group recently reported a case of cellular DF arising on an acral surface that
demonstrated strong nuclear expression of ERG, but ancillary testing failed to detect an EWSR1SMAD3 fusion. [18]This result further questions the specificity of ERG for vascular tumors and
provides the basis for the current study. In this pilot study, the expression pattern of ERG was
explored in a larger sample of conventional and cellular forms of cutaneous dermatofibromas,
hypertrophic scars-keloids, and DFSP. It was hypothesized that there would be increased
expression of ERG in dermatofibromas in comparison to the other two neoplasms.
Materials and Methods
After institutional review board approval (#15028), immunohistochemical analysis for
ERG (EP111, prediluted, Dako) was performed on fifteen sequentially encountered cases of
dermatofibroma (both conventional and cellular types) from routine clinical practice. Only cases
in which the bulk of the tumor was captured in the biopsy or excision specimens were assessed.
Ten keloid scars and nine DFSPs were also stained as control comparators. Slides were prepared
on a PT Link and Autostainer Link 48 (Dako). Primary antibody was visualized using peroxidase
as a detection system (Dako). ERG protein showed nuclear localization. Immunoreactivity was
scored as percentage positivity (S0: no staining, S1: <10% staining, S2: 10%-50% staining, S3:
>50% staining) and intensity (I0: none, I1: mild, I2: moderate, I3: strong).[19] The nuclear
staining intensity of normal endothelial cells was used as a positive control, as has been
previously described.[20] Descriptive statistical analyses were performed using Microsoft Excel
software.
Results

Immunohistochemical analysis for ERG was performed on fifteen DFs, ten keloids, and
nine DFSPs. Patient age, sex, and tumor location for all three neoplasm types were consistent
with characteristic findings for these lesions (Table 1). Biopsies of all three entities revealed
classic histomorphological features on hematoxylin and eosin staining (Figures 1-3).
Conventional DFs demonstrated plate-like epidermal acanthosis overlying a heavily collagenized
dermis containing interstitial stellate-appearing spindled cells with peripheral collagen trapping.
Cellular DFs contained similar epidermal changes and peripheral collagen trapping but with a
more tightly packed and often fascicular arrangement of plumper spindled cells. DFSPs were
characterized by a storiform arrangement of tightly packed monomorphous spindled cells, often
with extension into the fat lobules. Hypertrophic scars-keloids demonstrated a haphazard
arrangement of heavily collagenized and edematous fascicles with few interweaving fibroblasts
and myofibroblasts.
Consistent nuclear expression of ERG was found in DFs, with all fifteen specimens
demonstrating >50% of staining (S3). There was variability in the intensity of the staining with
over half the DF specimens displaying a strong pattern (I3) (8/15, 53%), 33% demonstrating a
moderate pattern (I2) (5/15), and 13% demonstrating a weak pattern (I1) (2/15) (Figure 1 and 4).
DFSPs demonstrated no staining (S0) in a third of the specimens (3/9, 33%), <10% staining in
22% of the specimens (2/9), 10%-50% staining in 33% of specimens (3/10), and >50% staining
in 11% of specimens (1/9). For DFSPs with positive staining, the intensity was mild (I1) for all
lesions (Figure 2 and 4). In keloids, no staining (S0) was found in 8/10 (80%) of the tissue
specimens, with the remaining 2/10 displaying <10% staining (S1) of mild intensity (I1) (Figure
3 and 4).

Discussion
Dermatofibroma, the most commonly encountered cutaneous mesenchymal spindle cell
neoplasm, is most often diagnosed based on histomorphological criteria alone. Numerous
subtypes have been recognized, including conventional, cellular, hemosiderotic, aneurysmal,
heavily lipidized, deep-variant, and atypical (with monster cells).[21-26] The differential
diagnosis most commonly includes DFSP, dermatomyofibroma, hypomelanotic blue nevus, and
scar. Immunohistochemistry is seldom necessary but can be useful in superficially-sampled
specimens precluding complete architectural evaluation. Panels with some combination of:
myogenic markers (smooth muscle actin [SMA], desmin), endothelial markers (CD31),
melanocytic markers (HMB-45, Melan-A), and other markers: (Factor 13a, CD34, Stromelysin
3, D2-40) have historically been used to help distinguish between DF and other potential
mimickers.[4, 27]
In particular, differentiating DF from DFSP can occasionally be problematic despite the
utility of the above markers. There is a tendency for dermatofibroma to express CD34 at its
periphery and lose expression of Factor 13a in its cellular forms, making a distinction from
DFSP challenging.[28] Moreover, rare cases of DFSP may lose CD34 expression, most
commonly in the context of fibrosarcomatous transformation.[29] In recent years, there has been
increased utilization of next-generation sequencing panels to confirm the presence of relevant
fusions in this context (such as COL1A1-PDGFB) to increase diagnostic accuracy. However, these
assays remain costly and are not readily available in many small community-based practices.
In this small pilot study, we found that DFs demonstrate consistent immunohistochemical
expression of ERG. This was in contrast to DFSP and hypertrophic-keloidal scars, which
demonstrated negligible expression on the basis of both percent positivity and staining intensity.

This finding is significant for several reasons. First, the skin-derived cell of origin in DF and
DFSP remains largely unknown. DFs are reported to follow trauma in approximately one-fifth of
patients, which would suggest a reactive process for initial development.[30] The presence of
strong ERG expression in DF might imply that this tumor is derived from a pluripotent stem cell
with the potential to proceed down an endothelial or fibrohistiocytic pathway (with trauma
perhaps activating the latter). On the other hand, dermatofibrosarcoma protuberans is thought to
originate from an undifferentiated mesenchymal stem cell with neurologic, muscular, and
fibroblastic components or from a dermal stem cell.[30] The negligible expression of ERG in
DFSP evident in this study lends further support to the hypothesis that these two tumors are more
distinct than they are similar in regard to their biological derivation.
ERG may prove to be a useful stain in the clinical setting of a partial biopsy specimen
when DF and DFSP are both considerations based on histomorphology. Additionally, the newly
described acral spindled cell ESFT may not be unique in its expression of ERG and could
theoretically exist on the spectrum of fibrous histiocytoma, albeit with an additional
characteristic genetic event more likely to occur on an acral site. Finally, the lack of unique ERG
expression in ESFT demonstrates that ERG staining may not be a helpful adjunct in
differentiating this entity from other cutaneous spindle cell neoplasms. Limitations of this study
are its small sample size, particularly the fewer cases of DFSP examined. Additionally, only two
variants of dermatofibroma were analyzed. Further studies with larger cohorts and assessment of
additional DF variants will be required to validate these findings.

Figure Legends

Figure 1. ERG staining of Dermatofibroma. (A) Conventional type dermatofibroma with bland
spindle cells arranged in a storiform pattern with hyalinized collagen bundles. ERG
immunohistochemistry: >50% staining (S3) is demonstrated with strong intensity (I3). (B)
Cellular type dermatofibroma with uniform spindle cells arranged in a storiform pattern. ERG
immunohistochemistry: >50% staining (S3) is demonstrated with strong intensity (I3). Low and
high power fields. Left: Hematoxylin and eosin (H&E). Right: immunohistochemical staining for
ERG.

Figure 2. ERG staining of Dermatofibrosarcoma protuberans. (A-B) Representative DFSP
biopsies. ERG positivity of 10-50% is demonstrated in both sections. Low and high power
fields. Left: Hematoxylin and eosin (H&E). Right: immunohistochemical staining for ERG.

Figure 3. ERG staining of keloid scars. (A-B) Representative keloid biopsies. Absent to minimal
ERG positivity is demonstrated. Low and high power fields. Left: Hematoxylin and eosin
(H&E). Right: immunohistochemical staining for ERG.

Figure 4: ERG Immunoreactivity as demonstrated by intensity and percent positivity.
Dermatofibromas consistently demonstrated high ERG positivity of >50% staining regardless of
intensity score, with all lesions having an intensity score of 1 or greater, compared to keloids and
dermatofibrosarcoma protuberans.
Table 1. Patient Demographics and Lesion Location

Tissue Type
Dermatofibroma
(n=15)

Mean Age (+/- SD)
45 (+/- 15.2)

Sex
M: 3
F: 12

Location Frequency (%)
Thigh (40%)
Lower leg (13%)
Forearm (20%)
Hip (7%)
Cheek (7%)
Shoulder/back (13%)

Keloid
(n=10)

32 (+/- 17.9)

M: 3
F: 7

Helix (40%)
Earlobe (50%)
Jaw (10%)

Dermatofibrosarcoma
protuberans
(n=9)

45 (+/- 12.6)

M: 4
F: 5

Shoulder/back (56%)
Scalp (11%)
Thigh/buttock (22%)
Abdominal wall (11%)
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